SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to exceptionally high short interest fueling intense short squeeze speculation, amplified by recent global regulatory approvals for its Anktiva cancer treatment. The community is rallying behind Dr. Patrick Soon-Shiong's vision for a potential chemo-free cancer solution, actively discussing the drug's expanding market potential and the increasing pressure on short sellers.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending following its Q4 earnings, which revealed a wider-than-expected loss despite revenue beating estimates, alongside news of a 12% workforce reduction and concerns over future share dilution. The community is heavily discussing the company's high cash burn, its challenging path to profitability, and the lack of a permanent CEO, while some optimists point to revenue growth and institutional investor interest as potential positives.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community anticipates momentum around the upcoming '4/20' period, actively promoting it as a 'culture coin' on Solana for the global cannabis community. Discussions highlight its long-term vision and the broader potential of cannabis, citing recent research and policy developments, despite some skepticism about volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community discussion explodes following Donald Trump's State of the Union address, with supporters hailing his speech while critics accuse him of delivering a 'clown show' full of lies, alongside renewed chatter around tariffs and ongoing Epstein claims.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is actively discussed due to a potential short squeeze, fueled by Tether's increasing ownership and substantial investment commitments for advertising and cloud services, alongside its strategic acquisition of Northern Data for AI infrastructure and the rollout of its 'Rumble Shorts' feature.

DHT Holdings, Inc. engages in the operation of a fleet of crude oil tankers. It operates through its integrated management companies in Monaco, Singapore, and Oslo, Norway. The company was founded in 2005 and is headquartered in Hamilton, Bermuda.

DHT Holdings Inc

DHT Holdings is trending as a pure-play VLCC tanker company capitalizing on global tariffs and geopolitical tensions that are extending oil shipping routes and tightening vessel supply, leading to skyrocketing charter rates. The community is highly bullish, viewing it as a "dividend monster" with a 100% net income payout policy, expecting significant future payouts.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is surging following its Japan PMDA marketing approval for Alpha DaRT and encouraging clinical updates for a second Glioblastoma (GBM) patient. The community is highly bullish, anticipating a significant breakout as institutional interest grows and the company transitions to global commercialization of its physics-based 'universal killer' cancer treatment.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HPQ is actively trending as its CEO's departure to PayPal compounds investor concern over recent weak guidance and rising memory costs, yet a strong contingent of the community sees deep value in its dividend yield and long-term AI PC potential at current depressed levels.

Pieverse

PIEVERSE is seeing significant community discussion around potential short squeezes and liquidations, with traders actively punishing bears. Concurrently, the crypto is trending amidst broader conversations linking it to ongoing scam concerns within the Pi Coin ecosystem.

FIST is the governance token of FstSwap, a decentralized exchange protocol based on BSC Binance Smart Chain, with a total of 200 million tokens in full circulation

Fistbump

FIST CRYPTO is trending as it's being heavily tagged alongside promotional messages for the newly launched MIGA token, with the community actively discussing an immediate airdrop opportunity for those who purchase MIGA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company's Q4 revenue rose to $202.1 million, but net income fell to $24.3 million.</li><li>Corcept said demand for its Cushing syndrome business surged in 2025, with record prescriptions and prescribers.</li><li>Corcept pushed back on the FDA’s decision to reject Relacorilant in December, saying that an April FDA meeting will be critical to determining next steps.</li></ul>Shares of Corcept Therapeutics, Inc. (CORT) slipped in extended trading on Tuesday after weaker-than-expected fourth-quarter (Q4) profit, as investors weighed the setback to its Cushing syndrome drug ahead of a key FDA meeting in April.<a href="https://stocktwits.com/symbol/CORT">CORT stock</a> jumped over 3% in Tuesday’s regular session.<h2 class="st-heading-2">CORT Q4 Results And 2026 Outlook</h2>Corcept reported Q4 revenue of $202.1 million, up from $181.9 million a year earlier but below expectations, while net income fell to $24.3 million, or $0.2 per diluted share, from $30.7 million, or $0.26 per share, also missing estimates.For the full year, revenue rose to $761.4 million from $675.0 million in 2024, while net income declined to $99.7 million from $141.2 million. Corcept guided for full-year 2026 revenue of $900 million to $1 billion.&nbsp;“In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism’s true prevalence and the necessity of appropriate treatment,” CEO Joseph K. Belanoff said, adding that there was a record number of new prescriptions and prescribers.However, Belanoff noted that growth was partially constrained by capacity issues and operational disruptions tied to a specialty pharmacy transition in Q4. He said the transition is now complete, and February is on track to be a record month for new patient starts.<h2 class="st-heading-2">FDA Rejection Keeps Focus On Relacorilant</h2>Investor attention remains centered on Relacorilant after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter in December, refusing approval of the drug for patients with hypercortisolism, also known as Cushing syndrome.In an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cort-shares-plummer-on-fda-drug-rejection-letter-reveal/cmySqTUR4SV">amended letter</a> published last month, the FDA said the late-stage trial results were insufficient to demonstrate effectiveness and flagged concerns around drug-induced liver injury. The agency also said it had raised concerns during pre-submission meetings about the adequacy of Corcept’s clinical development program, particularly regarding the assessment of effects on hypertension, and requested new clinical data and risk mitigation strategies.While the FDA acknowledged that Corcept’s pivotal Grace trial met its primary endpoint and that confirmatory evidence was provided, it said it could not reach a “favorable benefit-risk assessment” without additional evidence in December.<h2 class="st-heading-2">Corcept Pushes Back On FDA Decision</h2>On Tuesday’s earnings call, Corcept pushed back on the FDA’s conclusions and said an April FDA meeting will be critical to understanding the decision.Gary Robb, the company’s chief business officer, said Corcept believes the data “clearly met the hurdle for approval” and were consistent with those supporting previously approved treatments. “The confirmatory evidence we provided also met its endpoint until the agency mentioned sort of an analysis at the end that they performed that we had never seen and really can't replicate,” he added.&nbsp;“There is daylight between our position and their position,” Robb said, adding that the April meeting is intended to clarify the FDA’s thinking and determine next steps.Belanoff cited results from the company’s Catalyst study showing that treating hypercortisolism in certain patients led to symptom improvement. He said it is too early to say whether Corcept will pursue a new randomized trial.<h2 class="st-heading-2">Pipeline Beyond Cushing Syndrome</h2>Separately, Corcept said its New Drug Application for Relacorilant in platinum-resistant ovarian cancer remains under FDA review, with a July 11 deadline for the FDA to decide whether to approve the drug, and a European decision expected later this year.&nbsp;The company also outlined multiple ongoing and planned studies across oncology, metabolic disease and (a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=Amyotrophic+Lateral+Sclerosis&amp;sca_esv=82030d20fc0d5849&amp;sxsrf=ANbL-n6CsXNcCbD0Jf2HDjdwkbZaPdUv9g%3A1772002173901&amp;ei=fZueaaXPNuOo4-EPjc7WmAQ&amp;biw=1920&amp;bih=911&amp;ved=2ahUKEwj-udm2h_SSAxX1xjgGHc8qLfQQgK4QegYIAAgAEAQ&amp;uact=5&amp;oq=als+full+form%5C&amp;gs_lp=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_E8IHBzAuNC44LjHIBzWACAA&amp;sclient=gws-wiz-serp">myotrophic lateral sclerosis</a>) ALS, including a planned Phase 3 trial of Dazucorilant in ALS by mid-year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CORT was ‘bullish’ amid a 1,200% surge in 24-hour&nbsp; message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cort_ss_png_60f385c217.webp" alt="cort ss.png" width="966" height="140"><figcaption>CORT sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “CORT is a solid, growing company with multiple self-funded catalysts span across endocrinology and oncology. The current SP is an once-in-life-time bargain. GLTA! “<stembedurl>https://stocktwits.com/gucag006/message/645809500</stembedurl>Another user said, “Beaten down and an absolute steal at these prices. This company is going nowhere, buy and hold.”<stembedurl>https://stocktwits.com/The_Scientist/message/645785513</stembedurl>CORT stock has risen 5% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on the screen of a tablet

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst 

The company guided for $900 million to $1 billion in 2026 revenue.

Equity

Corcept Therapeutics Q4 Earnings Call Highlights

Corcept Therapeutics (NASDAQ:CORT) reported higher revenue in 2025 and issued 2026 guidance as executives used the company's fourth-quarter earnings call to address two major setbacks: an adverse...

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for...

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc. CORT Stockholder Notice: Shareholder Rights Law Firm...

Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.07 EPS

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) posted its earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, missing analysts' consensus estimates of...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30...

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline Corcept Therapeutics (CORT) Litigation: Hagens...

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit...

$CORT Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&amp;D and SG&amp;A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept&#39;s profits in 2026 and beyond.

Stocktwits

Corcept Therapeutics Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&D and SG&A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept's profits in 2026 and beyond.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.08	--	--	N/A
Q4 '25	$0.33	$0.20	-39.30%	MISSED
Q3 '25	$0.13	$0.16	18.98%	BEAT
Q2 '25	$0.19	$0.29	54.67%	BEAT
Q1 '25	$0.14	$0.17	19.30%	BEAT

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest CORT News

CORTCorcept Therapeutics Inc